Russell Investments Group
CCCC icon

Russell Investments Group’s C4 Therapeutics CCCC Stock Holding History

Russell Investments Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-95,822
Closed -$178K – 3220
2023
Q3 		$178K Buy
95,822
+17,689
+23% +$54K ﹤0.01% 2512
2023
Q2 		$215K Buy
78,133
+19,099
+32% +$61.4K ﹤0.01% 2459
2023
Q1 		$185K Buy
59,034
+13,798
+31% +$81.2K ﹤0.01% 2491
2022
Q4 		$267K Buy
45,236
+7,243
+19% +$60.1K ﹤0.01% 2494
2022
Q3 		$332K Sell
37,993
-648
-2% -$6.73K ﹤0.01% 2393
2022
Q2 		$290K Buy
+38,641
New +$340K ﹤0.01% 2448
2021
Q4 		– Sell
-5,056
Closed -$225K – 3002
2021
Q3 		$225K Buy
5,056
+4,494
+800% +$192K ﹤0.01% 2742
2021
Q2 		$21K Buy
+562
New +$20.1K ﹤0.01% 3175

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Russell Investments Group's CCCC Position: Q4 2023 in Review

Russell Investments Group sold out of C4 Therapeutics (CCCC) in Q4 2023, closing a stake of 95,822 shares — an estimated $178K sold.

Russell Investments Group first reported a position in CCCC in Q2 2021 and held it in 8 quarters. The position peaked at $332K in Q3 2022. 92 funds tracked by Wall St. Rank hold CCCC as of Q4 2023.

  • Russell Investments Group reported no remaining C4 Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Russell Investments Group sold 95,822 C4 Therapeutics shares in Q4 2023, an estimated $178K.
  • Russell Investments Group first reported a position in C4 Therapeutics in Q2 2021 and held it in 8 quarters.
  • Russell Investments Group's C4 Therapeutics position peaked at $332K in Q3 2022.
  • 92 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2023.

Based on Russell Investments Group's 13F filing for Q4 2023, filed 5 Feb 2024.